AI-Powered Medical Search Engine OpenEvidence Inks Major Content Deals, Reshaping Clinical Decision Support

OpenEvidence, an artificial intelligence startup founded in 2022, has secured significant content partnerships with two of the most prestigious medical journal publishers, positioning itself as a formidable player in the rapidly evolving landscape of AI-powered clinical decision support tools.

JAMA Network and NEJM Group Join Forces with OpenEvidence

In a move that promises to revolutionize how clinicians access and utilize medical information, OpenEvidence has announced multi-year content agreements with both the JAMA Network and NEJM Group. These partnerships will allow OpenEvidence to incorporate content from a total of 13 JAMA Network journals and several NEJM publications into its AI-powered medical search engine and generative AI chatbot.

Dr. Kirsten Bibbins-Domingo, Editor-in-Chief of JAMA and the JAMA Network, emphasized the importance of making peer-reviewed science more accessible to practicing clinicians. The collaboration with OpenEvidence will enable the delivery of high-quality scientific evidence from across JAMA's 13 journals directly to clinicians at the point of care.

Similarly, the deal with NEJM Group encompasses all published content and multimedia from 1990 forward from various NEJM publications, including the New England Journal of Medicine, NEJM Evidence, NEJM AI, NEJM Catalyst, and NEJM Journal Watch.

Rapid Growth and Industry Impact

OpenEvidence has experienced remarkable growth since its inception. The company claims that more than a third of doctors in the United States now use its platform, with over 50,000 verified clinicians registering each month. The platform is actively used across more than 10,000 hospitals and medical centers nationwide, handling an impressive 7.2 million clinical consultations monthly.

This rapid adoption has not gone unnoticed by investors. In February, OpenEvidence secured a $75 million funding round led by Sequoia, valuing the company at $1 billion. This financial backing, coupled with its expanding content partnerships, positions OpenEvidence as a significant disruptor in the clinical decision support market.

Competition and Collaboration in the AI-Powered Medical Information Landscape

As OpenEvidence gains traction, it faces competition from established players like UpToDate, owned by Wolters Kluwer. UpToDate, with over 30 years in the market, is also embracing AI technologies through partnerships with companies like Abridge and Corti AI.

The digital transformation of healthcare has long sought to deliver trusted, evidence-based clinical decision support to clinicians at the point of care. Dr. Robert Wachter, Chair of the Department of Medicine at UCSF, views AI as a significant leap forward in achieving this goal. He expressed confidence that the partnership between JAMA and OpenEvidence will benefit both clinicians and patients.

As the landscape of medical information delivery continues to evolve, the integration of AI technologies with authoritative content from leading medical journals promises to enhance clinical decision-making and ultimately improve patient care.